ArticlePPAR research2008
PPARgamma Inhibitors as Novel Tubulin-Targeting Agents.
Article in PPAR research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Microtubule disruption and apoptotic induction by Vibrio cholerae haemagglutinin protease: Implications for anticancer therapy in colon and gastric tumours.The Indian journal of medical research · 2026Article
- Malformin A1-mediated cytotoxicity in ovarian cancer cells occurs through pyroptosis and autophagy.FEBS open bio · 2026Article
- Role of Ciminalum-4-thiazolidinone Hybrids in Molecular NF-κB Dependent Pathways.International journal of molecular sciences · 2024Article
- Antiproliferative and Pro-Apoptotic Activity and Tubulin Dynamics Modulation of 1Molecules (Basel, Switzerland) · 2024Article
- Evaluating the Therapeutic Potential of Curcumin and Synthetic Derivatives: A Computational Approach to Anti-Obesity Treatments.International journal of molecular sciences · 2024Article
- Tubulin couples death receptor 5 to regulate apoptosis.Oncotarget · 2018Article
- A possible regulatory link between Twist 1 and PPARγ gene regulation in 3T3-L1 adipocytes.Lipids in health and disease · 2016Article
- A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo.Scientific reports · 2015Article
- Targeting microtubules by natural agents for cancer therapy.Molecular cancer therapeutics · 2014Review
- Effect of angiotensin II type 2 receptor-interacting protein on adipose tissue function via modulation of macrophage polarization.PloS one · 2013Article
- Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts.Investigational new drugs · 2012Article
- PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study.PPAR research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microtubule-targeting agents (MTAs) are a very successful class of cancer drugs with therapeutic benefits in both hematopoietic and solid tumors. However, resistance to these drugs is a significant problem. Current MTAs bind to microtubules, and/or to their constituent tubulin heterodimers, and affect microtubule polymerization and dynamics. The PPARgamma inhibitor T0070907 can reduce tubulin levels in colorectal cancer cell lines and suppress tumor growth in a murine xenograft model. T0070907 does not alter microtubule polymerization in vitro, and does not appear to work by triggering modulation of tubulin RNA levels subsequent to decreased polymerization. This observation suggests the possible development of antimicrotubule drugs that work by a novel mechanism, and implies the presence of cancer therapeutic targets that have not yet been exploited. This review summarizes what is known about PPARgamma inhibitors and cancer cell death, with emphasis on the tubulin phenotype and PPAR-dependence, and identifies potential mechanisms of action.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.